Background: The inherited susceptibility of common, complex diseases may be caused by 26 rare, 'monogenic' pathogenic variants or by the cumulative effect of numerous common, 27 'polygenic' variants. As such, comprehensive genome interpretation could involve two distinct 28 genetic testing technologies --high coverage next generation sequencing for known genes to 29 detect pathogenic variants and a genome-wide genotyping array followed by imputation to 30 calculate genome-wide polygenic scores (GPSs). Here we assessed the feasibility and 31 accuracy of using low coverage whole genome sequencing (lcWGS) as an alternative to 32 genotyping arrays to calculate GPSs. 33 34 Methods: First, we performed downsampling and imputation of WGS data from ten individuals 35 to assess concordance with known genotypes. Second, we assessed the correlation between 36
7 after removing the 61 individuals who were suspected to have a high GPSCAD based on multi-140 gene panel and off-target sequencing data to avoid artificial inflation of the correlation 141 coefficient. Two individuals who reported no personal history of CAD but were suspected to 142 have a high GPSCAD failed genotyping (quality control call rate of < 97%) and lcWGS (overall 143 coverage of < 0.5X), leaving a total of 182 individuals for analyses. 144
145
The diverse ancestry data set included a total of 120 samples from the following populations 146 from 1KGP: Han Chinese in Beijing, China (CHB); Yoruba in Ibadan, Nigeria (YRI); Gujarati 147 Indian from Houston, Texas (GIH); Americans of African Ancestry in Southwest USA (ASW); 148
Mexican Ancestry from Los Angeles, USA (MXL); and Puerto Ricans from Puerto Rico (PUR) 149 (see Supplementary Table 3 , Additional File 1; Figure 1B ). Four samples, including NA18917 150 and NA19147 from the YRI population and NA19729 and NA19785 from the MXL population, 151
were below the target 0.5X coverage and removed from analyses. 152
153
The clinical cohort included DNA samples from 11,502 individuals whose healthcare provider 154 had ordered a Color multi-gene panel test ( Figure 1B ). All individuals 1) had 90% or greater 155 European genetic ancestry calculated using fastNGSadmix [9] using 1KPG as the reference 156 panel, 2) self-identified as 'Caucasian', 3) provided history of whether they had a clinical 157 diagnosis of CAD, BC, or AF, and 4) did not have pathogenic or likely pathogenic variants 158 detected in the multi-gene NGS panel test, as previously described [10] (see Supplementary  159 Methods, Additional File 2). Demographics are provided in Supplementary For the pipeline validation data set, aligned reads were downsampled using SAMtools [11] to 185 2.0X, 1.0X, 0.75X, 0.5X, 0.4X, 0.25X, and 0.1X coverage. For the technical concordance cohort, 186 aligned reads were downsampled to 1.0X, 0.75X, 0.5X, 0.4X, 0.25X, and 0.1X coverage. In a 187 few cases in the technical concordance cohort, the primary samples had fewer reads than the 188 target downsample. In those situations, all of the reads were retained. For example, if the 189 primary sample only had 0.8X coverage, when downsampled to 1.0X, all reads were retained.
9
Downsampling was repeated using two independent seeds in SAMtools. Once the 191 downsampled data was generated, the imputation was repeated to generate imputed genotypes 192 using only the downsampled reads. 193 Imputation was performed using the genotype likelihood imputation option implemented in 216 BEAGLE 4.1 [14] . This imputation used default parameters except with a model scale 217 parameter of 2 and the number of phasing iterations to 0. A custom reference panel was 218 constructed for each sample being imputed by selecting the 250 most similar samples to that 219 sample from 1KGP Phase 3 release using Identity-by-State (IBS) comparison. A reference 220 panel size of 250 was selected to best balance imputation run time and accuracy (see Genotypes were filtered according to the manufacturer's recommendations, removing loci with 241 greater than 5% global missingness and those that significantly deviated from Hardy-Weinberg 242 equilibrium. In addition, all A/T and G/C SNPs were removed due to potential strand 243 inconsistencies. Each of the remaining SNPs were aligned with the hg19 reference sequence to 244 correctly code the reference alleles as allele 1, matching the sequencing data. Imputation accuracy on the genotyped samples was assessed on 470,363 sites that were 258 included on the genotyping array at different allele frequency buckets: 257,362 sites with greater 259 than 5% allele frequency, 119,978 sites between 1-5% allele frequency, and 93,022 sites with 260 less than 1% allele frequency. Imputation quality was assessed through site-specific dosage r 2 261 comparing with genotype values from the genotyping array. 262
263

GPS selection 264
The GPSs for CAD [3], BC [8], and AF [3] were previously published and selected based on 265 their demonstrated ability to accurately predict and stratify disease risk as well as identify 266 individuals at risk comparable to monogenic disease. GPSCAD contained 6,630,150 12 polymorphisms, GPSBC contained 3,820 polymorphisms, and GPSAF contained 6,730,541 268 polymorphisms. All loci included in these scores were included in the imputation SNP loci. 269
270
GPS normalization 271
In the clinical cohort, raw GPSs were normalized by taking the standardized residual of the 272 predicted score after correction for the first 10 principal components (PC) of ancestry [16] . PCs 273 were calculated by projecting lcWGS samples into 10 dimensional PC analysis (PCA) space 274 using the LASER program [17] . A combination of samples from 1KGP and the Human Origins 275
[18] project were used as a reference for the projection. 276
277
RESULTS 278
Development and validation of imputation pipeline for lcWGS 279
Previous studies have evaluated the potential use of lcWGS in local ancestry deconvolution, 280 complex trait association studies, and detection of rare genetic variants [4] [5] [6] . To assess the 281 feasibility and accuracy of this approach for GPSs, we first developed an imputation pipeline 282 that reads raw fastq sequence data and generates a vcf with imputed site information at 21.7 283 million sites (imputation SNP loci) ( Figure 1A, B ). Briefly, reads are aligned to the reference 284 genome and filtered for duplicates and low quality. Using this BAM file, we then calculate 285 genotype likelihoods and impute expected genotypes using 1KGP as the imputation reference 286 panel. 287
288
To validate this imputation pipeline, we performed hcWGS and downsampling on seven 289 samples from different 1KGP populations and a trio of Ashkenazi Jewish GIAB samples 290 (pipeline validation data set) to varying depths of coverage from 2.0X to 0.1X (See 291
Supplementary Table 1 , Additional File 2). We used the published genotype calls for each of 292 these samples as truth data and found that imputation accuracy was above 0.90 r 2 for all 293 samples at 0.5X and higher ( Figure 2 ). As expected, this was correlated with sequencing depth, 294 with diminishing gains observed at coverages above 1.0X. While imputation accuracy was 295 similar across diverse populations, it was slightly reduced in the Colombian sample (HG01485), 296 likely due to complex local ancestry related to admixture, and in the Yoruban sample 297 (NA19240), likely due to the shorter blocks of linkage disequilibrium and higher genetic diversity 298 in Africa [19] . Taken together, these data suggest that at sequencing depth at or above 0.5X, 299 our pipeline has similar imputation accuracy to genotyping array-based imputation across 300 individuals from multiple populations. As such, we set 0.5X as a quality control for success and 301 removed samples with coverage below this threshold in subsequent analyses. 302 303
Technical concordance between GPSs calculated from lcWGS and genotyping array 304
To assess the technical concordance of using lcWGS to calculate GPSs, we performed low 305 coverage sequencing and used genotyping arrays on DNA from 184 individuals (technical 306 concordance cohort) ( Figure 1B ). This concordance assessment was restricted to individuals of 307 European ancestry to most closely align with the populations used for GPS training and 308 validation. 309
310
We first compared the lcWGS genotype dosages with a subset of variants directly genotyped (n 311 = 470,362) on the genotyping array to assess imputation performance. Assuming the typed loci 312 called on the genotyping array as 'true', we observed an average imputation r 2 > 0.90 at 0.5X 313 depth for variants with global minor allele frequency (MAF) greater than 5% (see Supplementary  314 Figure 2, Additional File 3). As expected, imputation accuracy was highest for variants with 315 higher MAF. For lower frequency variants, we saw a reduction in imputation accuracy, as 316 expected, with r 2 > 0.85 for variants at 1% to 5% MAF and r 2 > 0.80 for variants less than 1% 317 global MAF. Taken together, this demonstrates that lcWGS has high accuracy in this test 318 setting. 319
We then calculated previously published GPSs for CAD [3] , BC [8], and AF [3] on each sample 321 using genotyping array data or lcWGS data. We found that GPSCAD, GPSBC, and GPSAF were 322 highly correlated ( Figure 3A-C) , with the score mean (Student t-test p = 0.17) and variance (F 323 test p = 0.91) equivalent between lcWGS and the genotyping array. The correlations of GPSCAD 324 and GPSAF (r 2 = 0.98 and r 2 = 0.97, respectively) were slightly higher than that of GPSBC (r 2 = 325 0.93), which could be due to 1) the smaller number of loci in GPSBC (6.6 million compared to 326 3820 SNPs), 2) differences in allele frequencies between SNPs with high weights, and/or 3) the 327 fact that GPSBC was trained and validated on a different genotyping array, the OncoArray, than 328 the Axiom UK Biobank Array used in this study [8] . 329
330
The technical concordance cohort ranged in coverage from 0.54X to 1.76X with a mean 331 coverage of 1.24X, and we have shown that depth can impact imputation performance --depth 332 increases above 0.5X have a smaller but measurable effect on imputation performance ( Figure  333 2; see Supplementary Figure 2 , Additional File 3). To determine the low coverage sequencing 334 depth required for GPS accuracy, we used SAMtools to downsample the lcWGS data in this 335 cohort to 1.0X, 0.75X, 0.5X, 0.4X, 0.25X, and 0.1X. We found that GPSCAD, GPSBC, and GPSAF 336 are robust to lcWGS sequencing depth 0.5X and that coverages do not systematically bias GPS 337 calculations in a specific direction (see Supplementary Figure 3 and Supplementary Figure 4 , 338 Additional File 3), indicating that samples above 0.5X with small changes in coverage variation 339 can be combined for downstream analysis. In addition, the correlation increases logarithmically 340 as coverage increases (see Supplementary Figure 5 , Additional File 3). These data 341 demonstrate high correlation between GPSs from lcWGS data and genotyping array in a 342 randomly selected sample. Interestingly, correlation at 0.1X was still high enough that GPSs at 343 this coverage may have research utility, suggesting that significant amounts of data regarding panel sequencing studies to allow for GPS calculation. Taken together, these data demonstrate 346 that lcWGS provides equivalent accuracy for calculation of GPSs, with sequencing coverage as 347 low as 0.5X. 348 349
Assessment of imputation performance and technical concordance across diverse 350 populations 351
To further assess the performance of our imputation pipeline across diverse populations, we 352 performed lcWGS on 120 additional samples from six 1KGP populations (CHB, GIH, YRI, ASW, 353 MXL, and PUR; see Supplementary Table 3 , Additional File 1) that represent the range of 354 ancestry observed in admixed populations (diverse ancestry data set). We compared genotypes 355 imputed using our lcWGS pipeline to known 1KGP WGS data and found that imputation 356 accuracy was above 0.90 r 2 for all samples (range 0.94 -0.97) ( Figure 4A ). In addition, we 357 found that GPS calculated from lcWGS data and GPS calculated from the Phase 3 1KGP WGS 358 data release have a high correlation, with an r 2 value of 0.98, 0.91, and 0.98 for CAD, BC, and 359 AF, respectively ( Figure 4B-D) . These results suggest that lcWGS can enable accurate 360 imputation and calculation of GPSs in diverse populations. 361 362
Association of lcWGS-calculated GPSs with disease phenotypes in a clinical cohort 363
Previous studies have demonstrated the association of GPSs with prevalent disease using 364 genotyping arrays [3, 8, [20] [21] [22] and hcWGS [16] . To observe the performance of lcWGS-365 calculated GPSs in a large population, we performed low coverage sequencing on 11,502 366 European individuals (clinical cohort) (See Supplementary Table 2 , Additional File 1) and 367 calculated GPSCAD, GPSBC, and GPSAF for each individual. Raw GPSs were normalized by 368 taking the standardized residual of the predicted score after correction for the first 10 PCAs (see 369 Supplementary Figure 6 , Additional File 3) [16, 23] . First, we note that there are no major outliers scores formed an approximately normal distribution for each (see Supplementary Figure 7 , 372 Additional File 3). Each of the GPSs were strongly associated with self-reported history of 373 disease, with effect estimates comparable to prior reports using genotyping arrays to calculate 374 GPS --GPSCAD (OR per standard deviation = 1.59 (1.32 -1.92), n = 11,010), GPSBC (OR per 375 standard deviation = 1.56 (1.45 -1.68); n = 8722), and GPSAF (OR per standard deviation = 376 1.28 (1.12 -1.46); n = 10,303) ( Figure 5) . 377
378
Previous studies have noted significantly increased disease prevalence among individuals in the 379 extreme tails of the GPS distribution when compared to the remainder of the population [3, 8] . 380
We replicated this observation by assessing the prevalence of disease in the highest 5% of the 381 GPS distribution for each of the three diseases, noting odds ratios of 4.5 (2.62 -7.74), 2.62 382
(2.04 -3.36), and 1.96 (1.24 -3.11) for GPSCAD, GPSBC, and GPSAF, respectively. 383 384 Area under the curve (AUC) is an additional metric used to assess the ability of a given risk 385 factor to discriminate between affected cases and disease-free controls. When only the GPS 386 was included in the prediction model, GPSCAD had an AUC of 0.60, GPSBC had an AUC of 0.63, 387 and GPSAF had an AUC of 0.57. The additional inclusion of age and sex increased the AUCs to 388 0.86 for GPSCAD, 0.78 for GPSBC, and 0.78 for GPSAF. For each of these three common, 389 complex diseases, the magnitude of associations with clinical disease and AUC metrics were 390 consistent with previous publications [3, 8] . Taken together, these results suggest that lcWGS-391 calculated GPSs can accurately stratify risk with comparable accuracy to previously published 392 GPS-disease associations calculated on the basis of genotyping array data. 393
394
DISCUSSION 395
For the past two decades, genotyping array-based GWAS and imputation have been the driving variably downsampled hcWGS and lcWGS data sets. While the efficiency of lcWGS has been 399 reported for other applications of statistical genetics [4] [5] [6] , we demonstrate that lcWGS achieves 400 similar technical concordance as the Axiom UK Biobank Array by Affymetrix for determining 401
GPSs. Furthermore, the imputation r 2 from lcWGS was greater than 90%, which is similar to the 402 imputation accuracy reported from other commercially-available genotyping arrays [24] . Taken 403 together, these data suggest that lcWGS has comparable accuracy to genotyping arrays for 404 assessment of common variants and subsequent calculation of GPSs. 405
406
Our finding that lcWGS can be used for accurate genotyping and imputation of common genetic 407 variants has implications for the future of genomic research and medicine. Currently, disease 408 GWAS are performed using a variety of genotyping arrays that are designed to target specific 409 sets of genes or features, reducing imputation quality in regions that are not targeted [25] . 410 lcWGS enables less biased imputation than genotyping arrays by not pre-specifying the genetic 411 content that is included for assessment, as is necessary for genotyping arrays. Because initial 412 GWAS focused on populations with high homogeneity to reduce noise and increase fit of risk 413 stratification, many genotyping arrays were designed to capture common genetic variants based 414 on the linkage disequilibrium structure in European populations [26] . However, this 415 ascertainment bias reduces the imputation performance from genotyping array data in diverse 416 populations [27] [28] [29] . Imputation from lcWGS data reduces this bias by including all SNPs 417 observed in 1KGP populations as potential predictors. The effects of SNP selection bias are 418 also not equivalent across genotyping arrays, and therefore variants included in a GPS trained 419 and validated on one genotyping array may not be as predictive on another genotyping array 420 [30] . lcWGS systematically surveys variants independent of SNP selection bias and thus 421 provides one approach to overcome this issue. Our findings here demonstrate that GPSs 422 trained and validated on different genotyping arrays are transferable to lcWGS-calculated GPS. 423 1. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional 521 mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis 522 for the Global Burden of Disease Study 2010. Lancet. 2012; 380:2095-128. 523 2. Boyle EA, Li YI, Pritchard JK. An Expanded View of Complex Traits: From Polygenic to 524 Omnigenic. Cell. 2017; 169:1177-86 . 
